Delcath Systems, Inc. has announced the results of the CHOPIN randomized Phase 2 clinical trial, which were presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. The trial met its primary endpoint and investigated the combination of percutaneous hepatic perfusion (PHP) and immune checkpoint inhibitor (ICI) therapy in patients with metastatic uveal melanoma. Delcath will host a conference call and webcast on October 20, 2025, at 8:45 a.m. Eastern Time to discuss the CHOPIN Trial results, as well as provide an overview of financial results and company guidance. A replay of the webinar will be available on the company's website following the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251018759712) on October 18, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.